Search Results - "Dave, Hema"

Virus-Specific T Cells for Hematopoietic Stem Cell Transplantation by Dave, Hema, Bollard, Catherine

“…Purpose of Review During the period of T cell immune recovery after hematopoietic stem cell transplantation (HSCT), viral infections and reactivation are a…”
Get full text

Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia by Raskin, Scott, Van Pelt, Stacey, Toner, Keri, Balakrishnan, Preethi Bala, Dave, Hema, Bollard, Catherine M., Yvon, Eric

“…The synovial sarcoma X breakpoint 2 (SSX2) belongs to a multigene family of cancer-testis antigens and can be found overexpressed in multiple malignancies. Its…”
Get full text

Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells by Holland, Elizabeth M, Gonzalez, Corina, Levy, Elliot, Valera, Vladimir A, Chalfin, Heather, Klicka-Skeels, Jacquelyn, Yates, Bonnie, Kleiner, David E, Hadigan, Colleen, Dave, Hema, Shalabi, Haneen, Hickstein, Dennis D, Su, Helen C, Grimley, Michael, Freeman, Alexandra F, Shah, Nirali N

“…BK virus (BKV)-hemorrhagic cystitis (HC) is a well-known and rarely fatal complication of hematopoietic stem cell transplantation (HSCT). Treatment for BKV-HC…”
Get full text

Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies by Dave, Hema, Anver, Miriam R, Butcher, Donna O, Brown, Patrick, Khan, Javed, Wayne, Alan S, Baskar, Sivasubramanian, Rader, Christoph

“…Despite high cure rates for pediatric B-lineage acute lymphoblastic leukemia (B-ALL), short-term and long-term toxicities and chemoresistance are shortcomings…”
Get full text

SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report by McNerney, Kevin Owen, Richards, Rebecca M, Aguayo-Hiraldo, Paibel, Calkoen, Friso G, Talano, Julie-An, Moskop, Amy, Balduzzi, Adriana, Krajewski, Jennifer, Dave, Hema, Vatsayan, Anant, Callahan, Colleen, Liu, Hongyan, Li, Yimei, Davis, Kara Lynn, Maude, Shannon L

“…BackgroundImmunocompromised patients are at increased risk of SARS-CoV-2 infections. Patients undergoing chimeric antigen receptor (CAR) T-cell therapy for…”
Get full text

Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood by Dave, Hema, Luo, Min, Blaney, J W, Patel, Shabnum, Barese, Cecilia, Cruz, Conrad Russell, Shpall, Elizabeth J, Bollard, Catherine M, Hanley, Patrick J

“…Umbilical cord blood (CB) has emerged as an effective alternative donor source for hematopoietic stem cell transplantation. Despite this success, the prolonged…”
Get full text

T087: Brentuximab vedotin (Bv) Demonstrates Superior Event‐Free Survival in Pediatric High‐Risk Hodgkin Lymphoma by Castellino, Sharon M., Pei, Qinglin, Parsons, Susan K., Hodgson, David, McCarten, Kathleen, Horton, Terzah, Cho, Steve, Wu, Yue, Punnett, Angela, Dave, Hema, Henderson, Tara O., Hoppe, Bradford S., Charpentier, Ann‐Marie, Keller, Frank G., Kelly, Kara M.

Get full text

Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients by Abraham, Allistair A., John, Tami D., Keller, Michael D., Cruz, C. Russell N., Salem, Baheyeldin, Roesch, Lauren, Liu, Hao, Hoq, Fahmida, Grilley, Bambi J., Gee, Adrian P., Dave, Hema, Jacobsohn, David A., Krance, Robert A., Shpall, Elizabeth. J., Martinez, Caridad A., Hanley, Patrick J., Bollard, Catherine M.

“…Adoptive transfer of virus-specific T cells (VSTs) has been shown to be safe and effective in stem cell transplant recipients. However, the lack of…”
Get full text

Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents by Attarbaschi, Andishe, Abla, Oussama, Ronceray, Leila, Bansil, Shweta, Bomken, Simon, Burkhardt, Birgit, Ceppi, Francecso, Chiang, Alan K.S., Dave, Hema, Fedorova, Alina, Henry, Michael, Jazbec, Janez, Kabickova, Edita, Kotecha, Rishi S., Lazic, Jelena, Loeffen, Jan, Miakova, Natalia, Osumi, Tomoo, Pillon, Marta, Pourtsidis, Apostolos, Rigaud, Charlotte, Tamamyan, Gevorg, Tandon, Sneha, Uyttebroeck, Anne, Verdu-Amoros, Jamie, Woessmann, Wilhelm, Wrobel, Grazyna, Giulino-Roth, Lisa

“…•Children with PCNSL and no immunodeficiency have a good outcome when treated by a histological subtype–driven and radiation-free protocol.•New treatment…”
Get full text

Engineering cord blood to improve engraftment after cord blood transplant by Mehta, Rohtesh S, Dave, Hema, Bollard, Catherine M, Shpall, Elizabeth J

“…Umbilical cord blood transplant (CBT) has traditionally been associated with slower engraftment of neutrophils, delayed immune reconstitution and consequently…”
Get full text

Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C by Kulkarni, Girish S., Gupta, Shilpa, Necchi, Andrea, Shore, Neal D., Dave, Hema Kishore, Kapadia, Ekta, Zhao, Qing, Kamat, Ashish M.

“…TPS719 Background: In cohort A of the phase 2 KEYNOTE-057 study (NCT02625961), the PD-1 inhibitor pembrolizumab demonstrated antitumor activity (3-month…”
Get full text

Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma by Castellino, Sharon M., Pei, Qinglin, Parsons, Susan K., Hodgson, David, McCarten, Kathleen, Horton, Terzah, Cho, Steve, Wu, Yue, Punnett, Angela, Dave, Hema, Henderson, Tara O., Hoppe, Bradford S., Charpentier, Anne-Marie, Keller, Frank G., Kelly, Kara M.

“…A regimen substituting brentuximab vedotin for bleomycin improved 3-year event-free survival among children and adolescents with Hodgkin’s lymphoma by nearly…”
Get full text

Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) by Shore, Neal D., Gupta, Shilpa, Kulkarni, Girish S., Necchi, Andrea, Dave, Hema Kishore, Kapadia, Ekta, Zhao, Qing, Kamat, Ashish M.

“…TPS591 Background: The PD-1 inhibitor pembro showed antitumor activity in cohort A of the phase 2 KEYNOTE-057 study (NCT02625961), with 41% of pts with HR…”
Get full text

T-cell therapies for T-cell lymphoma by Toner, Keri, Bollard, Catherine M, Dave, Hema

“…AbstractT-cell lymphomas represent a subpopulation of non-Hodgkin lymphomas with poor outcomes when treated with conventional chemotherapy. A variety of novel…”
Get full text

Identifying Tumor-Specific Immune Response and Biomarkers of High-Risk Hodgkin Lymphoma Patients Treated with and without Brentuximab on Children's Oncology Group Trial AHOD1331 by Toner, Keri, Dave, Hema, Pezzella, Gloria, Pei, Qinglin, Horton, Terzah M., Kelly, Kara M., Roth, Lisa Giulino, Castellino, Sharon M., Bollard, Catherine M.

“…Introduction: There is an unmet need to examine anti-tumor immune responses and predictive biomarkers in the peripheral blood to guide effective combination…”
Get full text

Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy by Abdel-Azim, Hisham, Dave, Hema, Jordan, Kimberly, Rawlings-Rhea, Stephanie, Luong, Annie, Wilson, Ashley L.

“…Immune effector cell (IEC) therapies have revolutionized our approach to relapsed B-cell malignancies, and interest in the investigational use of IECs is…”
Get full text

Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted EPOCH‐R by Giulino‐Roth, Lisa, O'Donohue, Tara, Chen, Zhengming, Bartlett, Nancy L., LaCasce, Ann, Martin‐Doyle, William, Barth, Matthew J., Davies, Kimberly, Blum, Kristie A., Christian, Beth, Casulo, Carla, Smith, Sonali M., Godfrey, James, Termuhlen, Amanda, Oberley, Matthew J., Alexander, Sarah, Weitzman, Sheila, Appel, Burton, Mizukawa, Benjamin, Svoboda, Jakub, Afify, Zeinab, Pauly, Melinda, Dave, Hema, Gardner, Rebecca, Stephens, Deborah M., Zeitler, William A., Forlenza, Christopher, Levine, Jennifer, Williams, Michael E., Sima, Jody L., Bollard, Catherine M., Leonard, John P.

“…Summary Treatment with dose‐adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab (DA‐EPOCH‐R) has…”
Get full text

ROR1 and ROR2-novel targets for neuroblastoma by Dave, Hema, Butcher, Donna, Anver, Miriam, Bollard, Catherine M.

“…Background: Despite advances in immunotherapeutic strategies for neuroblastoma (NBL), relapse remains a significant cause of mortality for high risk patients…”
Get full text

Iatrogenic immunodeficiency-associated lymphoproliferative disorder in a child with B-cell acute lymphoblastic leukemia by Shahid, Sanam, Rossi, Christopher, Vyas, Pranav, Bollard, Catherine, Dave, Hema

“…Iatrogenic immunodeficiency-associated lymphoproliferative disorders (LPDs) are a group of lymphoid proliferations or lymphomas that are well known to be…”
Get full text

Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463) by Castellino, Sharon M., Pei, Qinglin, Parsons, Susan K., Hodgson, David C., McCarten, Kathleen, Punnett, Angela, Horton, Terzah M., Dave, Hema Kishore, Cho, Steve Y., Wu, Yue, Henderson, Tara O., Hoppe, Bradford, Keller, Frank G., Kelly, Kara

“…7504 Background: The anti-CD30 antibody drug conjugate, Brentuximab vedotin (Bv) is approved for adults with advanced stage HL but its use has not been…”
Get full text